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Introduction
Pulmonary mucormycosis is an uncommon but often lethal 
opportunistic infection. The occurrence of a hemothorax 
and the consecutive need of repetitive surgical interventions 
even increases the morbidity.
We present a case of pulmonary mucormycosis in an 
18-year-old woman with acute B-lymphoblastic leukemia. 
Despite long-term use of antifungal treatment, the infection 
persisted and could only be treated by surgery (Figure 1). 
Case presentation
An 18-year-old patient initially presented to her general 
practitioner with neck pain, nausea, fever, coughing 
and pain in the limbs. Her blood test showed signs of 
a lymphatic leukemia (leukocytosis with 68% blasts, 
thrombocytopenia of 106 g/L, anemia of 83 g/L), therefore 
she was admitted for elective workup to our hospital.
She presented with hypotony, tachycardia but without 
fever. She had cervical, inguinal, axillary and retroauricular 
lymphadenopathy and a palpable spleen. The cause was 
confirmed as an acute B-lymphoblastic CD20 negative, 
BCR-ABL1 negative leukemia (B-ALL). Treatment was 
started according to hyper-CVAD (cyclophosphamide, 
vincristine, adriamycin and dexamethasone) scheme but 
could not be completed due to a cerebrovascular insult with 
left side hemiparesis which was caused by a septic embolism 
in the context of generalized mucormycosis diagnosed by 
cerebral biopsy and pleural tissue. In the cerebral biopsy 
broad spectrum fungal PCR has been positive for Absidia 
corymbifera. Later in the sputum Rhizopus species could 
be detected by culture sequencing. Histopathological 
examination of the pleural tissue showed fungal hyphae 
in the initial thoracoscopy and vascular invasive fungal 
hyphae in the cerebral biopsy in concordance with Mucorales 
species. The proven invasive mucormycosis (1) was treated 
with dual antifungal therapy (liposomal amphotericin B, 
10 mg/kg with treatment breaks resp. dose reduction due to 
renal insufficiency and posaconazole, 4×300 mg/d orally as 
suspension). Three months later MRI confirmed a regression 
of the cerebral mucor which allowed to reduce the treatment 
to posaconazole only (serum levels of posaconazole have been 
checked regularly as adequate). Both the B-ALL and the 
mucormycosis continued to be in remission.
More than a year later the patient admitted herself to 
the emergency room because of severe hemoptysis. CT 
scan revealed a bleeding spot in the right lower lobe with 
signs of mycotic infection (Figure 2A,B). During that time 
posaconazole level has been adequate with 2.5 mg/mL.
We performed an open decortication with partial non-
anatomical resection of the lower and middle lobe of 
the right lung. To remove all the infected tissue a small 
part of the infiltrated diaphragm also had to be removed. 
Additionally, a vacuum (VAC)-sponge was placed in the 
thorax. The histological check-up confirmed the diagnosis 
of invasive mucormycosis by detection of fungal hyphae 
under direct macroscopy.
Case Report
Urokinase application for hemothorax in pulmonary mucormycosis 
Lucas Hodel1, Ilhan Inci1, Urs Schanz2, Bart Vrugt3, Walter Weder1, Sven Hillinger1
1Department of Thoracic Surgery, 2Department of Hematology, 3Department of Pathology, University Hospital Zurich, Zurich, Switzerland
Correspondence to: Sven Hillinger, MD. Department of Thoracic Surgery, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. 
Email: sven.hillinger@usz.ch.
Abstract: We present an exemplary case of an immunocompromised patient with pulmonary mucormycosis 
successfully treated by a combination of surgical removal of the mucor and urokinase to control the recurring 
hemothorax. The use of urokinase in hemothoraces is a way to reduce repetitive surgeries in weak patients.
Keywords: Hemothorax; pulmonary mucormycosis; leukemia
Submitted Aug 10, 2017. Accepted for publication Jan 26, 2018.
doi: 10.21037/jtd.2018.03.01
View this article at: http://dx.doi.org/10.21037/jtd.2018.03.01
178
E176
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(3):E175-E178jtd.amegroups.com
Hodel et al. Urokinase application for hemothorax in pulmonary mucormycosis
Postoperatively the patient presented in good condition, 
even though the chest X-ray showed a partial atelectasis in 
the right lower lobe, the remaining lung was adequately 
expanded. Antifungal therapy with posaconazole and 
amphotericin B was continued.
Five days later, a planned second look was performed with 
an additional change of the VAC-sponge. Eight days after the 
initial operation the sponge was changed again and a Goretex 
patch 10 cm × 8 cm for partial replacement of the diaphragm 
has been placed and the chest has been definitively closed.
Over the course of a week the X-rays showed progressive 
worsening, which led to the suspicion of a recurring hemothorax 
(Figure 2C). An emergency thoracotomy and two more open 
revisions were needed. Thereafter, the patient finally stabilized 
and was moved from intensive care unit to the ward.
Eight days later, to address the ongoing hemothorax 
problem we instilled urokinase (100,000 IU/100 mL) 
into the right thoracic cavity once daily for 10 days. Lung 
function and radiologic controls showed a steady improve 
with reduced infiltration and effusion.
Follow-up
A brain MRI showed a partial remission of the mucormycosis 
Figure 1 Time line of the patient course. VAC, vacuum; CVAD, cyclophosphamide, vincristine, adriamycin and dexamethasone.
Figure 2 Pre- and intra-operative findings. (A,B) Preoperative CT scans with mucormycosis affected right lower lobe (arrows); (C) recurrent 
hemothorax (arrows) with chest tube in correct position.
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and no new brain lesions. The patient’s left side hemiparesis 
continued to improve with ongoing physiotherapy. Forty-
seven days after the initial hospitalization the patient was 
discharged into rehabilitation.
Ten months after the pulmonary resection, the patient 
showed improvements in both lab parameters (normal, 
microscopic blood test, normal cell lysis parameters and 
minimal residual disease markers not detectable by PCR) 
and clinical presentation (Figure 3). She is in remission in 
leukemia and controlled mucormycosis under continuous 
posaconazole treatment.
Discussion
Among pulmonary mycoses aspergillosis, candidiasis 
and cryptococcosis are the most frequent types, whereas 
pulmonary infections with mucorales (2). Mucormycosis 
is an increasing dangerous and life-threatening disease 
caused by fungi of the order mucorales with a high 
mortality of around 50% (3). While in immunocompetent 
patients, phagocytes kill the mucorales by generating 
oxidative metabolites and cationic peptides defensins, 
immunocompromised patients are much more at risk (4).
One of the defining characteristics of invasive fungal 
infection in mucormycosis is vascular invasion, which can 
lead to thrombosis and necrosis. The fungus is likely to 
spread and is difficult to control surgically. In combination 
with aggressive treatment with antifungal agents, surgical 
resection of infected tissue up to anatomical resections can be 
performed safely even in haematological patients, however 
with a perioperative mortality of 5–10% (5). Important is the 
control of the underlying haematologic disease.
Though not as common as other opportunistic fungal 
infections such as aspergillosis or candidiasis, it continues to 
be a problem in immunocompromised patients.
The mortality rate for mucormycosis infections 
ranges from 40% to over 90% in patients with stem cell 
transplantation and dissemination, despite of state of the art 
medical care (6,7).
Early diagnosis of the fungus is the key of successful 
treatment. If possible, the underlying disease should be 
cured. Treatment for mucormycosis is a combination 
of antifungal medication, as in this case of neurological 
involvement high dose of liposomal amphotericin B and 
posaconazole for maintenance therapy (3) and if possible 
surgical debridement of the infected tissue. 
If present in the chest cavity it can lead to recurring 
hemothorax.
To fight the potentially serious hemothorax in intensive 
care medicine the usual approach is to either perform 
a thoracotomy or video-assisted thoracoscopic surgery 
(VATS) to drain the residual blood. In recent years, the use 
of a tissue plasminogen activator (tPA) such as urokinase, 
which liquefies the clotted hemothorax, has come up as a 
less invasive method for treatment (8). Fibrinolytic agents 
as streptokinase or urokinase have been used safely in 
the posttraumatic hemothorax setting (9) or after lung 
resections (10). The risk of relevant bleeding using these 
agents is described in the literature with 2–15% in mostly 
immunocompetent patients.
In our PubMed search, we could not find an example 
of a patient with mucormycosis who has been treated 
with urokinase. Due to the comorbidity in mucormycosis 
patients the risk of repeated surgery is relatively high.
A B
Figure 3 Follow-up. (A) CT scan 10 months after the initial open resection with good expansion of the remaining lung and no signs of 
infection; (B) mucor hyphae found in pleural tissue [Grocott (silver) staining, 400×].
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Our case shows the successful  treatment of  an 
immunocompromised patient with generalized mucormycosis 
using the combination of surgical removal of the infected 
tissue and antifungals. To minimize the need for repetitive 
surgery in recurrent hemothorax the use of urokinase is a 
treatment option.
It is of high importance to treat those patients in a 
multidisciplinary experienced center. Especially using a 
fibrinolytic agent in a situation like this requires a careful 
and tight monitoring of the patient course.
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